AxoGen (AXGN) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 25.6% year-over-year to $47.9 million, driven by higher unit volume, improved sales productivity, and commercial execution.

• Net loss narrowed to $1.9 million ($0.04/share) from $6.7 million ($0.16/share) last year; adjusted net income was $2.0 million ($0.05/share).

• Adjusted EBITDA improved to $5.6 million from a $0.2 million loss last year.

• Core accounts increased to 412, representing 65% of revenue, with strong account and sales force growth.

• Full launch of Avive+ Soft Tissue Matrix in June 2024, with positive initial feedback and continued adoption.

Financial highlights

• Q2 2024 revenue: $47.9 million (+25.6% YoY); gross profit: $35.3 million; gross margin: 73.8% (down from 77.7%).

• Operating expenses decreased to $35.8 million, mainly from lower R&D, royalty, and travel costs.

• Net loss narrowed to $1.9 million; adjusted net income was $2.0 million.

• Cash, cash equivalents, and investments totaled $27.1 million at quarter-end.

• Working capital at June 30, 2024: $58.8 million; current ratio: 3.5x.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $182–186 million; gross margin expected between 74% and 76%.

• Expects to be net cash flow positive cumulatively from April 1 through year-end 2024.

• Rolling BLA submission for Avance Nerve Graft expected to complete in Q3 2024, with potential FDA approval by mid-2025.